Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in Multiple Sclerosis
NCT03783416Phase 1Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jun 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing Ixazomib (NINLARO®) with Placebo (2 arms). Primary endpoints: Adverse Events at 24 months and Proportion of OCB IgG negative subjects at 24 months. Started Jun 2020; status: recruiting.
02
Drugs
ixazomib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03783416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783416.